Bevacizumab, a monoclonal antibody targeting VEGF, has shown encouraging anti-tumor effects in many solid tumors, however, its tumor-suppressive effects are limited in PAAD.16 One important reason is that tumors can secrete proangiogenic factors that promote tumor angiogenesis in a manner independent of VEGF in PAAD.35 Therefore, understanding VEGF-independent angiogenic pathways in PAAD will facilitate the development of new antiangiogenic drugs. This evidence concerns the gene VEGFA and neoplasm.